20/20 Biolabs, INC

8-K

Market Movers (8-K)

See all →
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Adjourns Shareholder Vote on Charter Amendment
20/20 Biolabs, Inc. reconvened its annual meeting to vote on a proposal to increase authorized shares, which was ultimately approved.
Delay expected
Capital raise
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Faces Nasdaq Delisting Concerns
20/20 Biolabs received a second notification from Nasdaq for failing to meet stockholders' equity requirements, compounding previous bid price non-compliance issues.
Worse than expected
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Advances FDA Strategy, Eyes Medicare Reimbursement
20/20 Biolabs presented its OneTest diagnostic, detailing FDA engagement, potential Medicare reimbursement pathways, and commercial progress, while also outlining a forward-looking M&A strategy.
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Annual Meeting: Director Election, Plan Approval, Adjournment
20/20 Biolabs held its annual meeting, electing directors, approving an equity plan, and adjourning a charter amendment vote.
Delay expected
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 BioLabs Reports Record Cancer Test Revenue, Boosts Cash
20/20 BioLabs announced record quarterly revenue for its multi-cancer early detection test, a 47% year-over-year increase, alongside a strengthened cash position and elimination of convertible note debt.
Capital raise
Better than expected
NASDAQ
AIDX
20/20 Biolabs, INC
8-K: 20/20 Biolabs Eyes Medicare Reimbursement for Cancer Test
20/20 Biolabs presented an investor webinar on August 5, 2026, detailing progress on its OneTest for Cancer and Longevity, emphasizing the potential impact of new Medicare reimbursement pathways for multi-cancer early detection tests.